NovoCure Limited Stock 12‑Month Price Target Cut to $21.33, Implies 62% Upside

NovoCure Limited's average stock price target was reduced by analysts from $25.71 to $21.33, with a range of $15 to $29. This implies a 62% upside from the Oct. 30 closing price. The consensus rating remains 'Buy' among 6 analysts, with 3 Buys and 3 Holds.

Original reporting
Published Oct 31, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NovoCure Limited Stock 12‑Month Price Target Cut to $21.33, Implies 62% Upside — source image
Decision brief

The 30-second read

$NVCRBearishLow
01

Why it matters

Analyst target revisions are a secondary catalyst; they rarely move the stock dramatically unless accompanied by new fundamentals.

02

Market read

Minor relevance; price‑target cut may cause modest short‑term price adjustment.

03

What to watch

Potential upcoming trial data or partnership news could offset the target reduction.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates analyst consensus price targets without new company disclosures.

Company-level read

Ticker impact

$NVCRBearishMedium confidence
Context

Analysts cut NovoCure's average price target to $21.33, down from $25.71, implying 62% upside from the Oct. 30 close.

Expected impact

potential downward pressure as the market prices in the lower target

Evidence & confidence

A 17% target cut is a material analyst downgrade that typically triggers sell‑side activity.

Market effects

May slightly dampen sentiment in the oncology biotech sector.

Limited to U.S. biotech investors.

Low global impact.

Counterpoint

Some investors may view the 62% upside as a buying opportunity despite the target cut.

Key entities

  • NovoCure Limited

    Biotech firm developing cancer immunotherapy.

Related articles

$NVCRLowAI 8/10

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

$NVCRMedAI 8/10

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

NovoCure's (NVCR) shares fell 6% after the FDA rejected its Optune Mya device for lung cancer brain metastases, citing uncertainty about clinical benefits. The company plans to meet with FDA officials to discuss a potential approval path. NovoCure's other Optune devices, Gio, Lua, and Pax, are approved and generating revenue, but the company remains unprofitable. The FDA's decision adds to investor concerns about competition from Revolution Medicines' Rasonque pill.

$NVCRHighAI 9/10

Novocure’s device for treating brain metastases rejected by FDA

The FDA rejected Novocure's PMA for Optune Mya, a device for treating brain metastases, citing uncertainty about clinical benefits. The FDA did not raise safety concerns. Novocure plans to discuss feedback with the FDA to explore approval options, but there is no guarantee of future approval. The company has FDA approvals for other TTFields therapies, including Optune Gio, Lua, and Pax.